Entities / Company
Moderna.
American biotechnology company
- Reports this week
- 8
- Active events
- 5
- Connections
- 329
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Moderna and Arcturus Therapeutics are being compared for investment as healthcare companies.Some support1 report
-
Arbutus Biopharma filed patent enforcement lawsuits against Pfizer and sued Moderna regarding LNP patent infringement.Some support4 reports
-
Moderna is being led through strategic pivots by CEO Stéphane Bancel.Well supported5 reports1 development inside
-
Scottish Mortgage Investment Trust, managed by Baillie Gifford, highlighted its key holdings in SpaceX and Moderna.Some support1 report
-
Moderna is advancing vaccine trials in the Democratic Republic of the Congo.Some support2 reports
Earlier this month
-
Getty Images provided the image source for an article involving Moderna.Some support1 report
-
In Alberta, Moderna doses are publicly funded while Pfizer shots are sought by private payers.Some support1 report
-
MarketBeat listed Regeneron Pharmaceuticals, AbbVie, and Moderna as stocks to watch on October 31, 2026.Some support3 reports
-
The European Medicines Agency is reviewing mRNA vaccine trials reported by Moderna and MSD.Some support1 report
-
Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.Well supported51 reports2 developments inside
-
Moderna and Merck developed a new therapy.Some support8 reports1 development inside
-
Moderna and Merck developed the intismeran autogene therapy.Some support1 report
-
Sweden has abolished the use of mRNA products manufactured by both Pfizer and Moderna.Some support1 report
-
Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.Well supported3 reports
-
Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.Some support1 report1 development inside
-
Moderna's therapy combined with Merck's drug in an Australian-led clinical trial.Some support1 report
-
Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.Some support1 report1 development inside
-
Korea-linked financial instruments contributed to market turnover on October 23, 2026.Some support1 report
-
Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.Some support4 reports
-
Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.Well supported9 reports
-
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Well supported21 reports10 developments inside
-
Moderna presented vaccine results at the ESMO meeting in Madrid, with RBC Capital Markets covering the company.Some support1 report
-
Moderna and Merck released study results, while execution staff warned of potential issues during Christa Pike's execution attempt.Some support1 report
-
Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.Well supported14 reports2 developments inside
-
Moderna and Iovance Biotherapeutics, alongside Dell, SanDisk, and MaxLinear, were noted among top stock gainers.Some support1 report
-
Allegations surfaced that FDA officials, including a safety data-mining expert, were involved in oversight failures regarding vaccine safety signals related to Moderna.Some support1 report2 developments inside
-
Johnson is investigating FDA records concerning adverse effects of Moderna vaccines.Some support3 reports
-
Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.Some support1 report1 development inside
-
Moderna and BioNTech are recognized as leaders in the personalized cancer vaccine space.Some support1 report
-
Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.Some support1 report
-
Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.Well supported4 reports1 development inside
-
Moderna's stock gains are being driven by FDA approval and the broader growth of AI businesses, as a Nasdaq constituent.Some support1 report
-
President Stephen Hoge sold shares of Moderna stock.Some support1 report
-
Moderna and Nvidia are being discussed in the context of stock market signals.Some support2 reports
-
India sought vaccines from Pfizer and Moderna during COVID-19, while Piyush Goyal emphasized the need for self-reliance.Some support2 reports
-
Multiple financial firms acquired, increased, or lessened stakes in Moderna shares, while the company president also sold shares.Some support1 report
-
Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.Some support1 report
One to three months ago
-
MarketBeat identified Micron Technology, Intel, and Moderna as Value stocks.Some support6 reports
-
Moderna and Pfizer are developing defenses against Lyme disease, while Tarsus offers a pill for tick threats, amid surveillance discussions.Well supported3 reports
-
Moderna's stock performance is tracked on Nasdaq while Leerink Partners leads a Nasdaq IPO, amid oil price volatility and AI regulation tests.Some support1 report
-
The White House announced new tariffs on Canadian imports while noting integrated supply chains and drug price headwinds affecting the healthcare sector.Some support1 report2 developments inside
-
Both Moderna and Pfizer utilize mRNA technology for gene therapy.Some support1 report
-
Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.Some support1 report
-
Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.Some support1 report
-
Australian researchers announced a global cancer vaccine breakthrough on August 20, 2026, which subsequently boosted Moderna's share price.Some support1 report
-
Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.Well supported3 reports1 development inside
-
Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Some support2 reports
-
Positive test results were reported for Moderna's flu vaccine.Some support2 reports
-
Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.Some support5 reports
-
Dolly Parton, whose roots are in rural Tennessee, donated $1 million to support COVID-19 research involving Moderna and Vanderbilt University.Well supported8 reports
-
Analysis suggests that both Moderna and Illumina stocks are currently overvalued.Some support1 report
-
Insider trading filings made with the SEC regarding Moderna stock sales by President Stephen Hoge.Well supported7 reports
-
Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.Well supported4 reports
-
Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.Some support2 reports1 development inside
-
Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.Some support3 reports
-
A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.Well supported3 reports
-
Apple Inc., NetApp, and Moderna were mentioned together in a market context on September 13, 2026.Some support2 reports
-
Simon Baker downgraded Moderna's stock rating from Neutral to Sell on September 3, 2026.Some support2 reports
-
MarketBeat provided average rating data for Moderna, while CLSA raised the rating and Jefferies reiterated a hold.Some support1 report
-
GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.Some support1 report2 developments inside
No events began in the chosen period. Widen it, or reset.
What's reaching Moderna
Events traced to Moderna, step by step, newest first- Trump's tariff threats may reshape pharma supply chains for ModernaModerna may face supply chain shifts and cost pressures from tariff threatsPossible
- Abbott's new rapid test could challenge Moderna in Canadian diagnostics marketAbbott's new multi-virus test may intensify competition for respiratory diagnostics in Canada.Possible
- Pfizer's ADC investment could increase competitive pressure on ModernaPfizer's strategic ADC investment may increase competitive pressure on ModernaPossible
- Stricter FDA standards may raise costs for Moderna's drug trialsStricter FDA standards may raise costs for Moderna's drug trialsPossible
- Moderna may face increased competition as US funding shifts focus to EuropeModerna may face increased competition as US funding shifts focus to EuropePossible
- How could the strengthening of MindWalk Holdings Corp. affect Moderna's competitive position?MindWalk's talent influx strengthens new AI competitor in biopharmaPossible
Around Moderna this week
News at the entities that move Moderna most-
FDA StructuralAn HHS official commented on an FDA program, following Marty Makary's departure from the agency.Moves Moderna
-
Pfizer OperationalA building collapse occurred in Brooklyn, following prior structural issues in a Manhattan skyscraper that was formerly Pfizer's headquarters.Moves Moderna
-
Dolly Parton TransactionalDolly Parton's family network facilitated an arms deal in Haiti.Moves Moderna
-
Merck KGaA OperationalJohn Cooper discussed Merck KGaA's bio-based solvents in October 2026.Moves Moderna
-
Food and Drug Administration StructuralSeaStar Medical submitted a premarket approval application to the FDA and discussed trial enrollment plans.Moves Moderna
-
Centers for Disease Control and Prevention StructuralThe Trump administration launched an offensive targeting the eradication of HIV.Moves Moderna
Connections
The 40 strongest of 329, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Merck Structural
Moderna and Merck maintain a deep structural partnership, jointly developing and supplying personalized mRNA cancer vaccines and combination therapies.
-
Stéphane Bancel Structural
Stéphane Bancel holds the formal role of Chief Executive Officer of Moderna.
-
Pfizer Operational
Moderna and Pfizer are intense, direct competitors in the biopharmaceutical sector, primarily vying for market share and technological dominance using mRNA platforms.
-
Dolly Parton Transactional
Dolly Parton donated $1 million to Moderna to support early COVID-19 vaccine research and development.
-
Merck KGaA Operational
Merck KGaA and Moderna maintain a strategic partnership focused on jointly developing and testing personalized mRNA cancer vaccines.
-
Nasdaq Structural
Moderna is a constituent of the Nasdaq-100 index, and its stock performance influences the index's overall movement.
-
MSD Operational
Moderna and MSD are actively collaborating on the joint development and clinical trials of autogene therapies and mRNA vaccines.
-
Robert Langer Structural
Robert Langer co-founded the biotech firm Moderna.
Show all 40 connections
-
Noubar Afeyan Structural
Noubar Afeyan serves as a cofounder and board chair of Moderna.
-
Food and Drug Administration Structural
The FDA formally evaluates, regulates, and grants market access approvals for Moderna's products.
-
Stephen Hoge Structural
Stephen Hoge serves as President of Moderna, overseeing its commercial, R&D, and manufacturing operations.
-
FDA Structural
The FDA formally regulates Moderna's pharmaceutical products, granting necessary approvals and setting guidelines for market entry and commercial viability.
-
Lakshmi Srinivasan Structural
Lakshmi Srinivasan previously held a leadership role at Moderna.
-
CNBC Operational
CNBC actively covers Moderna's corporate announcements and stock movements, while Moderna utilizes CNBC's platform for major communications.
-
Centers for Disease Control and Prevention Structural
CDC regulates Moderna's vaccine eligibility and operations, and Moderna receives large government contracts.
-
Novavax Operational
Novavax and Moderna are direct competitors in the vaccine market, vying for market share and influencing each other's stock performance.
-
National Cancer Institute Structural
NCI provides funding for Moderna's mRNA trials and reports on the success of the company's research.
-
David Berman Structural
David Berman serves as the Chief Development Officer at Moderna.
-
Vanderbilt University Medical Center Structural
Vanderbilt University Medical Center provided foundational research, partnership, and funding integral to Moderna's vaccine development.
-
European Commission Structural
The European Commission formally approved the mCOMBRIAX vaccine and subsequently entered into a procurement contract with Moderna.
-
Wade Davis Structural
Wade Davis serves as the senior vice president for digital at Moderna.
-
Walgreens Operational
Walgreens serves as a key distribution point, utilizing its locations to make Moderna vaccines available to the public.
-
Stephanie Lee Structural
Stephanie Lee serves as a representative for Moderna.
-
Memorial Sloan Kettering Cancer Center Operational
Moderna and Memorial Sloan Kettering Cancer Center are actively partnering on personalized cancer vaccine trials and technology development.
-
Donald Trump Structural
Moderna's operations and funding are directly influenced by the policy decisions and regulatory actions of Donald Trump's administration.
-
Coalition for Epidemic Preparedness Innovations Operational
Moderna and CEPI are engaged in a strategic collaboration focused on developing and testing advanced vaccine candidates.
-
Mike Structural
Mike holds a formal governance role on the Moderna Board of Directors and Audit Committee.
-
Flagship Pioneering Structural
Flagship Pioneering is the founding entity responsible for the creation and structure of Moderna.
-
Michael McDonnell Structural
Michael McDonnell joined the Board of Directors of Moderna.
-
Derrick Rossi Structural
Derrick Rossi is a co-founder of the biotechnology company Moderna.
-
Invesco Structural
Invesco holds Moderna as a significant investment position within its various ETFs.
-
Eli Lilly and Company Operational
The two companies are direct competitors operating within the high-risk biopharmaceutical and healthcare sectors.
-
Health Canada Structural
Health Canada acts as the required regulatory body, providing authorization necessary for Moderna to conduct clinical studies in Canada.
-
Alberta Structural
Moderna doses are publicly funded by the government of Alberta for distribution and use.
-
Robert F. Kennedy Jr. Operational
RFK Jr.'s public challenges, lawsuits, and criticisms of mRNA technology actively influence Moderna's market perception and operational environment.
-
AbbVie Operational
AbbVie and Moderna are major competitors operating within the high-risk biotechnology and pharmaceutical sectors.
-
Department of Health & Human Services Structural
Moderna's research, funding, and operational projects are directly dependent on the grants, approvals, and funding decisions made by the Department of Health & Human Services.
-
Kennedy Operational
Kennedy criticized Moderna's mRNA technology and withdrew research grants for vaccine development.
-
National Institutes of Health Operational
NIH and Moderna are engaged in a partnership to accelerate national cancer vaccine development.
-
Stella Parton Transactional
Stella Parton made a donation that supported Moderna's research into mRNA vaccines.
History
Events by the month they beganNovember 2026
5 events- Moderna and Arcturus Therapeutics are being compared for investment as healthcare companies.
- Scottish Mortgage Investment Trust, managed by Baillie Gifford, highlighted its key holdings in SpaceX and Moderna.
- Moderna is advancing vaccine trials in the Democratic Republic of the Congo.
- Getty Images provided the image source for an article involving Moderna.
- In Alberta, Moderna doses are publicly funded while Pfizer shots are sought by private payers.
October 2026
28 events- MarketBeat listed Regeneron Pharmaceuticals, AbbVie, and Moderna as stocks to watch on October 31, 2026.
- The European Medicines Agency is reviewing mRNA vaccine trials reported by Moderna and MSD.
- Moderna and Merck developed the intismeran autogene therapy.
- Sweden has abolished the use of mRNA products manufactured by both Pfizer and Moderna.
- Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.
- Moderna's therapy combined with Merck's drug in an Australian-led clinical trial.
- Korea-linked financial instruments contributed to market turnover on October 23, 2026.
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Moderna presented vaccine results at the ESMO meeting in Madrid, with RBC Capital Markets covering the company.
- Moderna and Merck released study results, while execution staff warned of potential issues during Christa Pike's execution attempt.
- Moderna and Iovance Biotherapeutics, alongside Dell, SanDisk, and MaxLinear, were noted among top stock gainers.
- Johnson is investigating FDA records concerning adverse effects of Moderna vaccines.
- Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.
- Moderna and BioNTech are recognized as leaders in the personalized cancer vaccine space.
- Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.
- Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.
- Moderna's stock gains are being driven by FDA approval and the broader growth of AI businesses, as a Nasdaq constituent.
- President Stephen Hoge sold shares of Moderna stock.
- India sought vaccines from Pfizer and Moderna during COVID-19, while Piyush Goyal emphasized the need for self-reliance.
- Multiple financial firms acquired, increased, or lessened stakes in Moderna shares, while the company president also sold shares.
- Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.
- MarketBeat identified Micron Technology, Intel, and Moderna as Value stocks.
- Moderna and Pfizer are developing defenses against Lyme disease, while Tarsus offers a pill for tick threats, amid surveillance discussions.
- Moderna's stock performance is tracked on Nasdaq while Leerink Partners leads a Nasdaq IPO, amid oil price volatility and AI regulation tests.
- Both Moderna and Pfizer utilize mRNA technology for gene therapy.
- Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.
- Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.
- Australian researchers announced a global cancer vaccine breakthrough on August 20, 2026, which subsequently boosted Moderna's share price.
September 2026
8 events- Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.
- Analysis suggests that both Moderna and Illumina stocks are currently overvalued.
- Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.
- Apple Inc., NetApp, and Moderna were mentioned together in a market context on September 13, 2026.
- Simon Baker downgraded Moderna's stock rating from Neutral to Sell on September 3, 2026.
- MarketBeat provided average rating data for Moderna, while CLSA raised the rating and Jefferies reiterated a hold.
Show 3 earlier months
August 2026
8 events- Arbutus Biopharma filed patent enforcement lawsuits against Pfizer and sued Moderna regarding LNP patent infringement.
- Moderna and Merck developed a new therapy.
- Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Dolly Parton, whose roots are in rural Tennessee, donated $1 million to support COVID-19 research involving Moderna and Vanderbilt University.
- Insider trading filings made with the SEC regarding Moderna stock sales by President Stephen Hoge.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.
July 2026
1 eventJune 2026
10 events- Moderna is being led through strategic pivots by CEO Stéphane Bancel.
- Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Allegations surfaced that FDA officials, including a safety data-mining expert, were involved in oversight failures regarding vaccine safety signals related to Moderna.
- Moderna and Nvidia are being discussed in the context of stock market signals.
- The White House announced new tariffs on Canadian imports while noting integrated supply chains and drug price headwinds affecting the healthcare sector.
- Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.
- Positive test results were reported for Moderna's flu vaccine.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
- GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.